Table 1.
Basic characteristics of BCLC-B HCC patients undergoing TACE treatment (n = 531).
| Basic Characteristics | BCLC-B HCC |
|---|---|
| n = 531 | |
| Age (years), mean ± S.D. | 69.0 ± 12.3 |
| Gender, Male, n (%) | 412 (77.6) |
| HBsAg, Positive, n (%) | 244 (46.0) |
| Anti-HCV, Positive, n (%) | 180 (33.9) |
| Alcoholic, n (%) | 66 (12.4) |
| Cirrhosis, n (%) | 379 (71.4) |
| Platelet count (×104/μL), median (range) | 141 (22–601) |
| ALT (IU/L), median (range) | 46 (7–355) |
| AST (IU/L) †, median (range) | 54 (6–806) |
| INR, median (range) | 1.07 (0.85–14.50) |
| Albumin (g/dL), median (range) | 3.6 (2.1–4.9) |
| Total bilirubin (mg/dL), median (range) | 0.77 (0.19–3.79) |
| Child-Pugh class, A/B, n (%) | 459 (86.4)/72 (13.6) |
| ALBI grade, 1/2/3, n (%) | 167/327/37 (31.5/61.6/7.0) |
| Tumor size (cm), mean ± SD | 6.58 ± 3.72 |
| HBV-HCC (n = 220) | 7.05 ± 3.92 |
| HCV-HCC (n = 156) | 5.47 ± 2.93 |
| HBV-HCV-HCC (n = 24) | 6.21 ± 3.21 |
| Tumor location, Unilobar/Bilobar, n (%) | 273 (51.4)/258 (48.6) |
| Tumor number, ≥3/<3, n (%) | 269 (50.7)/262 (49.3) |
| Tumor size plus tumor number models | |
| Up-to-6, In/Out, n (%) | 83/448 (15.6/84.4) |
| Up-to-7, In/Out, n (%) | 165/366 (31.1/68.9) |
| Up-to-11, In/Out, n (%) | 390/141 (73.4/26.6) |
| Up-to-12, In/Out, n (%) | 424/107 (79.8/20.2) |
| AFP (ng/mL), median (range) | 50.33 (1.00–1,050,960.00) |
† One missing data; Abbreviations: BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; S.D., standard deviation; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; ALT, alanine transaminase; IU, international unit; AST, aspartate aminotransferase; INR, international normalized ratio; ALBI, Albumin-Bilirubin; AFP, alpha-fetoprotein.